Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
REVIEW PAPER
Takayasu arteritis: is disease activity assessment possible?
Online publication date: 2013-04-29
Reumatologia 2013;51(2):144-150
KEYWORDS
Takayasu arteritisdisease activitymagnetic resonance imagingpositron emission tomographyultrasonography
ABSTRACT
Takayasu arteritis is a rare disease of large arteries. Its onset is insidious and may be missed while the ongoing inflammation causes irreversible consequences: cardiovascular complications, vessel obstruction, vision loss and hypertension crisis. The disease is systemic; therefore patients are seen by various specialists: rheumatologist, ophthalmologist, cardiologist and surgeon. Current therapy affects only active inflammation whereas prolonged treatment with corticosteroids results in distant side effects and should not be overused. In order to estimate the effectiveness of the treatment and necessity of its modification it is essential to assess the activity of the inflammation.
In a diagnostic procedure ultrasonography (US) and magnetic resonance imaging (MRI) are of significant importance. Positron emission tomography (PET) seems to be sensitive but expensive, is not readily available and requires further validation. Laboratory indicators, such as interleukin 6, 12 and 18, are being checked as biomarkers of active disease but current data come from small studies. Studies on a complex scale assessing disease activity, such as DEI.Tak, are also being carried out. However, none of the present tools is universal.
In a diagnostic procedure ultrasonography (US) and magnetic resonance imaging (MRI) are of significant importance. Positron emission tomography (PET) seems to be sensitive but expensive, is not readily available and requires further validation. Laboratory indicators, such as interleukin 6, 12 and 18, are being checked as biomarkers of active disease but current data come from small studies. Studies on a complex scale assessing disease activity, such as DEI.Tak, are also being carried out. However, none of the present tools is universal.
REFERENCES (60)
1.
Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: a review. J Clin Pathol 2002; 55: 481-486.
2.
Choe YH, Han BK, Koh EM, et al. Takayasu's arteritis: assessment of disease activity with contrast-enhanced MR imaging. AJR Am J Roentgenol 2000; 175: 505-511.
3.
Park JH, Chung JW, Im JG, et al. Takayasu arteritis: evaluation of mural changes in the aorta and pulmonary artery with CT angiography. Radiology 1995; 196: 89-93.
4.
Kissin EY, Merkel PA. Diagnostic imaging in Takayasu arteritis. Curr Opin Rheumatol 2004; 16: 31-37.
5.
Aluquin VPR, Albano SA, Chan F, et al. Magnetic resonance imaging in the diagnosis and follow up of Takayasu’s arteritis in children. Ann Rheum Dis 2002; 61: 526-529.
6.
Akazawa H, Ikeda U, Yamamoto K, et al. Hypercoagulable state in patients with Takayasu’s arteritis. Thromb Haemost 1996; 75: 712-716.
7.
Yamazaki M, Takano H, Miyauchi H, et al. Detection of Takayasu arteritis in early stage by computed tomography. Int J Cardiol 2002; 85: 305-307.
8.
Paul JF, Fiessinger JN, Sapoval M, et al. Follow-up electron beam CT for the management of early phase Takayasu arteritis. J Comput Assist Tomogr 2001; 25: 924-931.
9.
Kim SY, Park JH, Chung JW, et al. Follow-up CT Evaluation of the mural changes in active Takayasu arteritis. Korean J Radiol 2007; 8: 286-294.
10.
Yoshida S. The spectrum of findings in supra-aortic Takayasu’s arteritis as seen on spiral CT angiography. Cardiovasc Intervent Radiol 2001; 24: 117-121.
11.
Tanigawa K, Eguchi K, Kitamura Y, et al. Magnetic resonance imaging detection of aortic and pulmonary artery wall thickening in the acute stage of Takayasu arteritis. Arthritis Rheum 1992; 35: 476-480.
12.
Andrews J, Al-Nahhas A, Pennell DJ, et al. Non-invasive imaging in the diagnosis and mamagement of Takayasu’s arteritis. Ann Rheum Dis 2004; 63: 995-1000.
13.
Tso E, Flamm SD, White RD, et al. Takayasu arteritis. Utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum 2002; 46: 1634-1642.
15.
Desia MY, Stone JH, Foo TK, et al. Delayed contrast-enhanced MRI of the aortic wall in Takayasu’s arteritis: initial experience. AJR Am J Roentgenol 2005; 184: 1427-1431.
16.
Yamada I, Numaro F, Suzuki S. Takayasu arteritis: evaluation with MR imaging. Radiology 1993; 188: 89-94.
17.
Webb M, Chambers A, Al-Nahhas A, et al. The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis. Eur J Nucl Med Mol Imaging 2004; 31: 627-634.
18.
Gupta R, Kavimandan A, Kumar R. Does PET-CT predict disease activity in Takayasu’s arteritis? Scand J Rheumatol 2008; 37: 237-239.
19.
Moreno D, Yuste JR, Rodriguez M, et al. Positron emission tomography use in the diagnosis and follow up of Takayasu’s arteritis. Ann Rhem Dis 2005; 64: 1091-1093.
20.
Derdelinekx I, Maes A, Bogaert J, et al. Positron emission tomography scan in the diagnosis and follow-up of aortitis of the thoracic aorta. Acta Cardiol 2000; 55: 193-195.
21.
Meller J, Strutz F, Siefker U, et al. Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur J Nucl Med Mol Imaging 2003; 30: 730-736.
22.
Tatsumi M, Cohade C, Nakamoto Y, et al. Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiol 2003; 229: 831-837.
23.
Blockmans D, Bley T, Schmidt W. Imaging for large-vessel vasculitis. Curr Opinion Rheumatol 2009; 21: 19-28.
24.
Andrews J, Mason JC. Takayasu’s arteritis - recent advances in imaging offer promise. Rheumatology 2007; 46: 6-15.
25.
Kobayashi Y, Ishii K, Oda K, et al. Aortic wall inflammation due to Takayasu arteritis imaged with 18F-FDG PET coregistered with enhanced CT. J Nucl Med 2005; 46: 917-922.
26.
Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68: 318-323.
27.
Schmidt WA. The role of color and power Doppler sonography in rheumatology. Nat Clin Pract Rheumatol 2007; 3: 35-42.
28.
Chaubal N, Dighe M, Shah M. Sonographic and color doppler findings in aortoarteritis (Takayasu arteritis). J Ultrasound Med 2004; 23: 937-944.
29.
Schmidt WA, Blockmans D. Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Curr Opinion in Rheumatology 2005; 17: 9-15.
30.
Raninen RO, Kupari MM, Hekali PE. Carotid and femoral artery stiffness in Takayasu’s arteritis. An ultrasound study. Scand J Rheumatol 2002; 31: 85-88.
31.
Ng WF, Fantin F, Ng C, et al. Increased arterial stiffness in patients with Takayasu’s arteritis. Rheumatol 2006; 45: 741-745.
32.
Schmidt WA, Nerenheim A, Seipelt E, et al. Diagnosis of early Takayasu arteritis with sonography. Rheumatology 2002; 41: 496-502. .
33.
Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep 2004; 6: 203-211.
34.
Cantu C, Pineda C, Barinagarrementeria F, et al. Noninvasive cerebrovascular assessment of Takayasu arteritis. Stroke 2000; 31: 2197-2202.
35.
Salvarani C, Cantini F, Boiardi L, Hunder GG. Laboratory investigations useful in giant cell arteritis and Takayasu’s arteritis. Clin Exp Rheumatol 2003; 21S: 23-28.
36.
Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33: 1129-1134.
37.
Sox HC Jr, Liang MH. The erythrocyte sedimentation rate. Guidelines for rational use. Ann Int Med 1986; 104: 515-523.
38.
Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
39.
Hall S, Barr W, Lie JT, et al. Takayasu arteritis: a study of 32 North American patients. Medicine (Baltimore) 1985; 64: 89-99.
40.
Vanoli M, Daina E, Salvarani C, et al.; Itaka Study Group. Takayasu's arteritis: A study of 104 Italian patients. Arthritis Rheum 2005; 53: 100-7.
41.
Eshaghian J, Goeken JA. C-reactive protein in giant cell (cranial, temporal) arteritis. Ophtalmology 1980; 87: 1160-1166.
42.
Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000; 30: 17-24.
43.
Park JR, Jones JG, Hazleman BL. Relationship of the erythrocyte sedimentation rate to acute phase proteins in polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis 1981; 40: 493-495.
44.
Hoffman GS, Ahmed AE. Surrogate markers of disease activity in patients with Takayasu arteritis. A preliminary report from The International Network for the Study of the Systemic Vasculitides (INSSYS). Int J Cardiol 1998; 66 Suppl 1: S191-S194.
45.
Seko Y, Sato O, Tagaki A, et al. Restricted usage of T-cell receptor Valpha-Vbeta genes in infiltrating cells in aortic tissue of patients with Takayasu's arteritis. Circulation 1996; 93: 1788-1790.
46.
Noris M, Daina E, Gamba S, et al. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation 1999; 100: 55-60.
47.
Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology 2006; 45: 545-548.
48.
Verma DK, Tripathy NK, Verma NS, Tiwari S. Interleukin 12 in Takayasu's arteritis: plasma concentrations and relationship with disease activity. J Rheumatol 2005; 32: 2361-2363.
49.
Tripathy NK, Sinha N, Nityanand S. Interleukin-8 in Takayasu's arteritis: plasma levels and relationship with disease activity. Clin Exp Rheumatol 2004; 22: 27-30.
50.
Park MC, Park YB, Jung SY, et al. Anti-endothelial cell antibodies and antiphospholipid antibodies in Takayasu's arteritis: correlations of their titers and isotype distributions with disease activity. Clin Exp Rheumatol 2006; 24 (2 Suppl 41): S10-S16.
51.
Nityanand S, Mishra K, Shrivastava S, et al. Autoantibodies against cardiolipin and endothelial cells in Takayasu's arteritis: prevalence and isotype distribution. Br J Rheumatol 1997; 36: 923-924.
52.
Navarro M, Cervera R, Font J, et al. Anti-endothelial cell antibodies in systemic autoimmune diseases: prevalence and clinical significance. Lupus 1997; 6: 521-526.
53.
Sima D, Thiele B, Turowski A, et al. Anti-endothelial antibodies in Takayasu’s arteritis. Arthritis Rheum 1994; 37: 441-443.
54.
Blank M, Krause I, Goldkorn T, et al. Monoclonal anti-endothelial cell antibodies from a patient with Takayasu’s arteritis activate endothelial cells from large vessels. Arthritis Rheum 1999; 42: 1421-1432.
55.
Eichhorn J, Sima D, Thiele B, et al. Anti-endothelial cell antibodies in Takayasu arteritis. Circulation 1996; 94: 2396-2401.
56.
Tripathy NK, Sinha N, Nityanand S. Antimonocyte antibodies in Takayasu’s arteritis: prevalence of and relation to disease activity. J Rheumatol 2003; 30: 2023-2026.
57.
Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med 1994; 120: 919-929.
58.
Sivakumar MR, Misra RN, Bacon PA. The Indian perspective of Takayasu arteritis and development of a disease extent index (DEI.Tak) to assess Takayasu arteritis. Rheumatology 2005; 44: iii 6-7.
59.
Aydin SZ, Yilmaz N, Akar S, et al. Assessement of disease activity and progression in Takayasu’s arteritis with Disease Extent Index-Takayasu. Rheumatology 2010; 49: 1889-1893.
60.
Direskeneli H, Aydin SZ, Kermani TA, et al. Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. J Rheumatol 2011; 38: 1471-1479.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
